By Lori Solomon HealthDay ReporterFRIDAY, June 20, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

Biotech stock KalVista has soared recently, as the firm looks to fundamentally change the treatment landscape for HAE ...

The U.S. Food and Drug Administration (FDA) has approved ANDEMBRY® (garadacimab-gxii), developed by CSL, as the first ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

BioCryst Pharmaceuticals (BCRX) announced that ORLADEYO (berotralstat) has been approved for national reimbursement in the Netherlands for routine prevention of hereditary angioedema (HAE) attacks in ...

The table below is a review of notable updates that occurred in May 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

However, being aware of early warning signs and symptoms of appendicitis may help with diagnosing and treating the condition as early as possible. People with acute appendicitis typically require ...

Yea. Results will be shared as a poster presentation from 12:00–1:00 pm BST in the Poster Zone. Impact of Delayed Treatment of Hereditary Angioedema Attacks: Insights from Patient Surveys Across ...

The NHS adds: "Some of these symptoms, including breast lumps, are very common and can be caused by other conditions. Having the symptoms does not definitely mean you have breast cancer ...